|
Sign In to gain access to subscriptions and/or personal tools.
|
Time of interferon-ß 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients
T. Kümpfel
Institute of Clinical Neuroimmunology, Klinikum Großhadern, Ludwig-Maximilians-Universität, Munich, Germany, tania.kuempfel{at}med.uni-muenchen.de
M. Schwan
Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany
Th. Pollmächer
Centre of Mental Health, Klinikum Ingolstadt, Ingoldstadt, Germany
A. Yassouridis
Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany
M. Uhr
Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany
C. Trenkwalder
Department of Clinical Neurophysiology, University of Goettingen, Germany
F. Weber
Max-Planck-Institute of Psychiatry, Sections of Neurology, Clinical Chemistry and Statistics, Munich, Germany
During initiation of interferon-beta (IFN-ß) therapy, many multiple sclerosis (MS) patients experience systemic side effects which may depend on the time point of IFN-ß injection. We investigated the time course of plasma hormone-, cytokine- and cytokine-receptor concentrations after the first injection of IFN-ß either at 8.00 a.m. (group A) or at 6.00 p.m. (group B) and quantified clinical side effects within the first 9 h in 16 medication free patients with relapsing-remitting MS. This investigation was repeated after 6-month IFN-ß therapy.
Plasma ACTH and cortisol concentrations followed their physiological rhythms, with lower levels in the evening compared to the morning, but raised earlier and stronger in group B after IFN-ß administration. IFN-ß injection in the evening led to a prompter increase of plasma IL-6 concentrations and temperature during the first hours and correlated to more intense clinical side effects compared to group A. Plasma IL-10 concentrations increased more in group A compared to group B, but sTNF-RI and sTNF-RII concentrations raised 7 h after IFN-ß injection only in group B. Acute effects on plasma hormone and cytokine concentrations adapted after 6-month IFN-ß treatment, while diurnal variations were still present. Baseline sTNF-RII concentrations were elevated after 6-month IFN-ß therapy only in group A.
Our results show that time point of IFN-ß injection has differential effects on acute changes of plasma hormone and cytokine concentrations and is related to systemic side effects. This may have implications on the tolerability and effectiveness of IFN-ß therapy. Multiple Sclerosis 2007; 13: 1138—1145. http://msj.sagepub.com
Key Words: time point of injection • interferon-ß • cytokine • hormones • side effects • multiple sclerosis
References
- PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 52: 1498—504.
- The IFNß Multiple sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655—61.[Abstract/Free Full Text]
- Neilley LK, Goodin DS, Goodkin DE, Hauser SL Side effect profile of interferon beta-1b in multiple sclerosis: results of an open label trial. Neurology 1996; 46: 552—54.[Abstract/Free Full Text]
- Goebel MU, Baase J., Pithan V., Exto MS, Saller B., Schedlowski M. et al. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology 2002; 27: 881—92.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kümpfel T., Then Bergh F, Pollmächer T., Holsboer F., Trenkwalder C. Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS. Neurology 2000; 55: 1231—33.[Abstract/Free Full Text]
- Ohno Y., Fujimoto M., Nishimura A., Aoki N. Change of peripheral levels of pituitary hormones and cytokines after injection of interferon (IFN)- ß in patients with chronic hepatitis C. J Clin Endocrinol Metabol 1998; 83: 3681—87.[CrossRef]
- Petrovsky N., McNair P., Harrison LC Diurnal rhythms of proinflammatory cytokines: Regulation by plasma cortisol and therapeutic implications. Cytokine 1998; 10: 307—12.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97: 155—69.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ozaydin M., Dede O., Dogan A., Aslan MS, Altinbas A., Ozturk M. et al. Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis in patients undergoing first elecvtive percutaneous coronary intervention. Am J Cardiol 2006; 97: 44—47.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cutolo M., Sulli A., Pizzorni C., Secchi ME, Soldano S., Seriolo B. et al. Circadian rhytms: glucocorticoids and arthritis. Ann N Y Acad Sci 2006; 1069: 289—99.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- McDonald WI, Compston A., Edan G., Goodkin D., Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121—27.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Montalban X., Duran I., Rio J., Saez-Torres I., Tintore M., Martinez- Caceres EM Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta? J Neurol 2000; 247: 259—62.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Nicoletti F., Marco R., Patti F., Zaccone P., L'Episcopo MR, Reggio E. et al. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-
 without significantly modifying those of IL-1ß, IL-2, IL-4 and tumor necrosis factor- . Cytokine 2000; 12: 682—87.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve] - Evans A., Main E., Zier K., Ikegaki N., Tartaglione Mkennett R, Lampson L. The effects of gamma interferon on natural killer and tumor cells of children with neuroblastoma. A preleminary report. Cancer 1989; 64: 1383—87.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pollmächer T., Mullington J., Korth C., Schrieber W., Hermann D., Orth A. et al. Diurnal variations in the human host response to endotoxin. J Infect Dis 1996; 174: 1040—45.[Web of Science][Medline]
[Order article via Infotrieve]
- Martinez-Caceres EM, Rio J., Barrau M., Duran BS, Borras BS, Tintore M. et al. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol 1998; 4: 682—85.
- Young MR, Metthews JP, Kanabrocki EL, Sothern RB, Roitman-Johnson B., Scheving LE Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor alpha and granulocyte.macrophage colony-stimulating factor in men. Chronobiol Int 1995; 12: 19—27.[Medline]
[Order article via Infotrieve]
- Petrovsky N. Towards a unified model of neuroendocrineimmune interaction. Immunol and Cell Biol 2001; 79: 350—57.[CrossRef]
- Ersoy E., Kus C., Sener U., Çoker I., Zorlu, Y. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 2005; 12: 208—11.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rep MH, Schrijver HM, van Lopik T., Hintzen RQ, Roos MT, Ader HJ et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J Neuroimmunol 1999; 96: 92—100.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Laske C., Oschmann P., Tofighi J., Kuehne SB, Diehl H., Bregenzer T. et al. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Acta Neurol Scand 2001; 103: 105—13.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rieckmann P., Kruse N., Nagelkerken L., Beckmann K., Miller D., Polmann C. et al. Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. J Neurol 2005; 252: 526—33.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457—65.[Abstract/Free Full Text]
- Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer 2003; 97: 155—69.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ohdo S. Changes in toxicity and effectiveness with timing of drug administration: implications for drug safety. Drug Saf 2003; 26: 999—1010.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
Multiple Sclerosis, Vol. 13, No. 9,
1138-1145 (2007)
DOI: 10.1177/1352458507078685
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
